Journal of diabetes and its complications最新文献

{"title":"Prevalence of cardiovascular and renal comorbidities among patients with type 2 diabetes routinely treated in the primary care setting in Greece: An epidemiological study (the RECARDIA study)","authors":"Nikolaos Papanas ,&nbsp;Vasileios Tsimihodimos ,&nbsp;Niki Katsiki ,&nbsp;John Doupis ,&nbsp;Emmanouil Pagkalos ,&nbsp;Nikos Nikas ,&nbsp;Nikos Papakonstantopoulos ,&nbsp;George Karpouzos ,&nbsp;Nikolaos Tentolouris","doi":"10.1016/j.jdiacomp.2025.109087","DOIUrl":"10.1016/j.jdiacomp.2025.109087","url":null,"abstract":"<div><h3>Aims</h3><div>This study aimed to generate real-world data on the prevalence of cardiovascular disease (CVD), including atherosclerotic CVD (ASCVD) and heart failure (HF), as well as chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) routinely treated in Greece.</div></div><div><h3>Methods</h3><div>This was a non-interventional, epidemiological, multicentre, cross-sectional and retrospective chart review study of T2DM patients attending a routine clinical visit at 198 outpatient primary care settings across Greece from November 2020 to February 2022.</div></div><div><h3>Results</h3><div>Among 2000 enrolled T2DM outpatients, the prevalence of ASCVD was 20.40 % (95 % confidence interval [CI]: 18.67 %–22.25 %), of HF 8.03 % (95 % CI: 6.67 %–9.63 %), and of CKD 49.55 % (95 % CI: 47.36 %–51.74 %). Hypertension was correlated with increased risk of ASCVD, HF or CKD, dyslipidaemia with ASCVD and CKD, obesity solely with HF, and smoking with ASCVD. Patients over 65 years were at higher risk of ASCVD, HF or CKD, whereas those with T2DM for ≥10 years had a higher risk of ASCVD or HF. Finally, males were more likely to have ASCVD</div></div><div><h3>Conclusions</h3><div>The present study confirms the high prevalence of CVD and CKD among Greek T2DM patients managed in primary care, that potentially qualify for new antidiabetic treatments with cardiovascular or renal benefits.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 8","pages":"Article 109087"},"PeriodicalIF":2.9,"publicationDate":"2025-05-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144124027","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical frailty scale as a tool to predict outcomes after lower extremity amputation among patients with diabetes: A retrospective cohort study","authors":"Hilma Tillqvist ,&nbsp;Miska Vuorlaakso ,&nbsp;Mika Helminen ,&nbsp;Juha Kiiski ,&nbsp;Ilkka Kaartinen","doi":"10.1016/j.jdiacomp.2025.109084","DOIUrl":"10.1016/j.jdiacomp.2025.109084","url":null,"abstract":"<div><h3>Aims</h3><div>The primary aim of this study was to investigate how the Clinical Frailty Scale (CFS) associates with survival of patients with diabetes after lower extremity amputation (LEA).</div></div><div><h3>Methods</h3><div>This retrospective cohort study included patients with diabetes undergoing nontraumatic LEA at Tampere University Hospital during 2007–2020. Kaplan-Meier and Cox regression analyses were performed to evaluate the effect of CFS on overall survival (OS), amputation-free survival (AFS) and leg salvage (LS).</div></div><div><h3>Results</h3><div>A total of 1043 patients with mean age 71.0 years were included. Compared to patients with low CFS (1, 2), scores 3–4 and 5–9 were associated with reduced OS (HR 1.821, <em>p</em> &lt; 0.001; HR 4.585, <em>p</em> &lt; 0.001), AFS (HR 1.575, <em>p</em> &lt; 0.001; HR 4.031, <em>p</em> &lt; 0.001) and LS (HR 1.435, <em>p</em> = 0.049; HR 2.478, <em>p</em> &lt; 0.001). The multivariable Cox regression analysis showed that CFS remained a significant predictor of OS, AFS and LS.</div></div><div><h3>Conclusions</h3><div>This study demonstrates a high prevalence of frailty among patients with diabetes undergoing LEA, suggesting that frailty assessment should be integrated into clinical decision-making for this patient population. The CFS score appears to be a promising tool for evaluating patients facing amputation to enhance survival rates.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 8","pages":"Article 109084"},"PeriodicalIF":2.9,"publicationDate":"2025-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144099303","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Joint effect of nicotine use and diabetes distress on glycemic control in young adults with type 1 diabetes","authors":"Enzo G. Plaitano ,&nbsp;Catherine Stanger","doi":"10.1016/j.jdiacomp.2025.109083","DOIUrl":"10.1016/j.jdiacomp.2025.109083","url":null,"abstract":"<div><div>Nicotine inhibits glucose metabolism. In this national cross-sectional analysis of 388 young adults with type 1 diabetes and above target glycemic control, vaping was the most common route of nicotine use, and heavy nicotine use plus higher type 1 diabetes distress was related to worse objective measures of glycemic control.</div><div><strong>Trial registration</strong>: <span><span>ClinicalTrials.gov</span><svg><path></path></svg></span> <span><span>NCT04646473</span><svg><path></path></svg></span>; <span><span>https://clinicaltrials.gov/ct2/show/NCT04646473</span><svg><path></path></svg></span>.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 8","pages":"Article 109083"},"PeriodicalIF":2.9,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Differential impact of short-term and long-term glycemic variability on peripheral nerve function in type 2 diabetes: A 5-year cohort study","authors":"Takamasa Iwamoto ,&nbsp;Machiko Morita ,&nbsp;Shuji Hidaka ,&nbsp;Kentaro Sada ,&nbsp;Miyuki Iwamoto ,&nbsp;Hirotaka Shibata","doi":"10.1016/j.jdiacomp.2025.109081","DOIUrl":"10.1016/j.jdiacomp.2025.109081","url":null,"abstract":"<div><h3>Aims</h3><div>Several studies have demonstrated the association between glycemic variability (GV) and diabetic peripheral neuropathy (DPN). However, none has compared the effects of short-term and long-term GV on DPN in a cohort. This study evaluates the association between short-term and long-term GV and peripheral nerve function in a cohort of outpatients with type 2 diabetes.</div></div><div><h3>Methods</h3><div>Overall, 230 patients who had continuously attended the outpatient hospital for 5 years were enrolled. Short-term GV was assessed using continuous glucose monitoring (FreeStyle Libre Pro®), focusing on metrics such as the glucose levels’' standard deviation and time in range. Long-term GV was evaluated by using visit-to-visit variability in glycated hemoglobin (HbA1c), including the HbA1c standard deviation and coefficient of variation. Nerve conduction was assessed using DPNCheck™ by measuring sural nerve action potential (SNAP) amplitude and sensory conduction velocity (SCV). Multiple regression models were built to determine independent associations of GV and HbA1c variability metrics with SCV and SNAP amplitude.</div></div><div><h3>Results</h3><div>Most short-term GV indices were not associated with SNAP amplitude but significantly correlated with SCV; these associations were not evident after adjusting for HbA1c. Long-term GV showed minimal correlation with SCV, while strong associations with SNAP amplitude persisted after adjusting for the 5-year mean HbA1c.</div></div><div><h3>Conclusions</h3><div>Our findings demonstrate that short-term and long-term GVs have differential impacts on peripheral nerve function in outpatients with type 2 diabetes; with short-term GV associated with SCV and long-term with SNAP amplitude.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 8","pages":"Article 109081"},"PeriodicalIF":2.9,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144147529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of initial combination therapy vs. step-therapy on adherence and persistence in drug naïve type 2 diabetes patients","authors":"Zahra Majd ,&nbsp;Hua Chen ,&nbsp;Michael L. Johnson ,&nbsp;Kim K. Birtcher ,&nbsp;Omar Serna ,&nbsp;Bilqees Fatima ,&nbsp;Susan Abughosh","doi":"10.1016/j.jdiacomp.2025.109080","DOIUrl":"10.1016/j.jdiacomp.2025.109080","url":null,"abstract":"<div><h3>Background/objectives</h3><div>Emerging evidence supports the early use of intensive combination treatments among type 2 diabetes (T2D) patients for rapid and sustained glycemic control. However, the impact of initial combination therapy on treatment adherence and persistence has not been explored. Therefore, we aimed to compare adherence and persistence to antidiabetic treatments between patients receiving initial combination therapy vs. conventional step-therapy.</div></div><div><h3>Materials and methods</h3><div>A retrospective cohort study of MarketScan® research database (2017–2019) was conducted. We included drug naïve T2D patients who received step-therapy or initial combination therapy and were continuously enrolled in Commercial, Medicare, or Medicaid health plans during the pre-index and follow-up period. Primary outcomes of interest were antidiabetic treatment adherence and persistence during the first year of treatment initiation.</div></div><div><h3>Results</h3><div>In the Commercial/Medicare population, out of the total 116,597 patients, 52 % were nonadherent and 58 % were nonpersistent. Similarly, in the Medicaid population of 18,295 patients, 63 % were nonadherent and 67 % were nonpersistent. Patients receiving step-therapy were more likely to be adherent compared to the initial combination group in both populations (Commercial/Medicare: OR 1.52, 95 % CI 1.46–1.57; Medicaid: OR 1.24, 95 % CI 1.11–1.38). Additionally, in the Commercial/Medicare population, the multivariable Cox regression model showed that the step-therapy cohort had a significantly lower hazard for time to non-persistence compared to the initial combination cohort (HR 0.9, 95 % CI 0.86–0.94). However, this was not significantly different in the Medicaid population.</div></div><div><h3>Conclusions</h3><div>This study suggests that step-therapy as an initial pharmacotherapy approach may be associated with improved adherence and persistence in managing diabetes compared to initial combination therapy.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 9","pages":"Article 109080"},"PeriodicalIF":2.9,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144178364","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"External validation of a clinical risk score for the presence of cardiovascular autonomic neuropathy in type 1 diabetes","authors":"Pietro Pertile,&nbsp;Ilenia D'Ippolito,&nbsp;Beatrice De Santis,&nbsp;Aikaterini Andreadi,&nbsp;Davide Lauro,&nbsp;Vincenza Spallone","doi":"10.1016/j.jdiacomp.2025.109066","DOIUrl":"10.1016/j.jdiacomp.2025.109066","url":null,"abstract":"<div><h3>Aims</h3><div>To validate in an independent external population a CAN Risk Score previously developed in type 1 diabetes (T1D) and validated for cardiovascular autonomic neuropathy (CAN) with a good diagnostic accuracy.</div></div><div><h3>Methods</h3><div>Forty-seven participants with T1D (age 47.7 ± 13.2 years, duration of diabetes 30.0 (19.0–40.5) years, 24 males) underwent 4 cardiovascular reflex tests (CARTs) to diagnose early and confirmed CAN (according to 1 or 2 abnormal results). CAN Risk Score was calculated from resting heart rate, HbA1c, retinopathy and/or nephropathy, cardiovascular disease, HDL cholesterol, systolic blood pressure and smoking (range 0–10).</div></div><div><h3>Results</h3><div>Eleven participants (23.4 %) had CAN. The CAN Risk Score was higher in subjects with overall CAN (early and confirmed) (<em>P</em> = 0.0498) and with confirmed CAN (<em>P</em> = 0.0142) compared to those without, and correlated with CARTs severity (rho = 0.32, <em>P</em> = 0.026), Expiration/Inspiration ratio (<em>r</em> = −0.33, <em>P</em> = 0.0258) and Valsalva ratio (<em>r</em> = −0.47, <em>P</em> = 0.0015). A CAN Risk Score ≥ 4 was found in 19 participants and was associated with the presence of confirmed CAN (<em>P</em> = 0.0129). The CAN Risk Score showed an area under the ROC curve (AUC) of 0.802 ± 0.080 for confirmed CAN, and at the cut-off of 4, sensitivity, specificity and negative predictive values of 85.71 %, 67.50 % and 96.43 %.</div></div><div><h3>Conclusions</h3><div>This study confirmed the diagnostic value of the CAN Risk Score and supports its inclusion in a diagnostic algorithm to identify candidates for CARTs, thereby reducing universal screening. Using routinely available clinical data as categorical variables, the score is easy to calculate and implement in clinical settings.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109066"},"PeriodicalIF":2.9,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143924393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the effect of Semaglutide as add-on therapy on glycemic control and continuous glucose monitoring outcomes in adults with type 1 diabetes: A two-year real-world data study","authors":"Ayman Al Hayek ,&nbsp;David C. Klonoff ,&nbsp;Wael M. Al Zahrani ,&nbsp;Suzan Eid Ibrahim ,&nbsp;Mohammed A. Al Dawish","doi":"10.1016/j.jdiacomp.2025.109064","DOIUrl":"10.1016/j.jdiacomp.2025.109064","url":null,"abstract":"<div><h3>Aims</h3><div>To evaluate the long-term efficacy of a GLP-1 receptor agonist (GLP-1RA, Semaglutide) as an adjunct to insulin therapy in adults with type 1 diabetes (T1D), using continuous glucose monitoring (CGM) metrics alongside weight and metabolic outcomes.</div></div><div><h3>Methods</h3><div>In this retrospective chart review of adults with T1D on intensive insulin therapy, GLP-1RA was initiated and maintained for two years. Glycemic and metabolic parameters were evaluated at baseline, 12 months (T12), and 24 months (T24) during combination therapy.</div></div><div><h3>Results</h3><div>A total of 67 adults with T1D (56.7 % males, 43.3 % females; mean age 31.8 years, SD: 6.11; mean diabetes duration 16.6 years, SD: 5.16) were included. By 24 months, we observed improved %TIR_70–180 from 46 % to 71 % and %TIR_70–140 from 28.1 % to 47.9 % (<em>p</em> <em>&lt;</em> <em>0.001 for both</em>). GRI, including CHypo and CHyper, showed sustained reductions, and glycemic variability improved, with CV% falling from 46.3 % to 33.6 % (<em>p</em> <em>&lt;</em> <em>0.001</em>). HbA1c improved from 8.2 % to 7.1 %, with total daily insulin dose decreasing from 1.4 to 0.7 IU/kg/day (<em>p</em> <em>&lt;</em> <em>0.001</em>). Body weight and lipid profile improved, with significant reductions in weight (<em>p</em> <em>&lt;</em> <em>0.001</em>), LDL (<em>p</em> <em>&lt;</em> <em>0.001</em>), and triglycerides (<em>p</em> <em>&lt;</em> <em>0.05</em>). No hospitalizations for DKA or major adverse cardiovascular events (MACE) occurred, and short discontinuation had no significant impact on metabolic or glycemic outcomes.</div></div><div><h3>Conclusions</h3><div>The adjunctive use of GLP-1RA in T1D shows potential for improving glycemic stability and metabolic parameters without increasing hypoglycemia risk. However, further studies are needed to confirm these effects across diverse populations and over more extended periods to fully establish their long-term efficacy and safety.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109064"},"PeriodicalIF":2.9,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143894577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Role of rs490683 variant in the promoter region of the ghrelin receptor gene on body weight and metabolic syndrome after a partial meal replacement hypocaloric diet","authors":"Daniel de Luis,&nbsp;Olatz Izaola,&nbsp;David Primo,&nbsp;Daniel Rico,&nbsp;Juan Jose López","doi":"10.1016/j.jdiacomp.2025.109062","DOIUrl":"10.1016/j.jdiacomp.2025.109062","url":null,"abstract":"<div><h3>Background and aims</h3><div>Few studies have evaluated the effect of rs490683 on weight loss. The objective of our study was to evaluate the role of this variant of <em>GHSR</em> gene on body weight loss and cardiovascular risk factors secondary to a partial meal replacement (pMR) hypocaloric diet.</div></div><div><h3>Methods</h3><div>96 individuals with a body mass index (BMI &gt; 35 kg/m²) were enrolled. Participants consumed a normocaloric, hyperproteic formula twice daily (12-w). Measurements were taken for body weight, BMI, fat mass, waist circumference, blood pressure, lipid profile, fasting insulin levels and HOMA-IR.</div></div><div><h3>Results</h3><div>The genotype was 70 patients (72.9 %) CC genotype, 19 patients(19.8 %) CG genotype, and 7 patients(7.3 %) GG genotype. The intake of calories, grams of carbohydrates, fats and proteins was higher at 12w in patients carrying the G allele. BMI (−3.5 ± 0.4 kg/m² vs −1.0 ± 0.2 kg/m² (<em>p</em> = 0.01)), body weight (−8.5 ± 1.0 kg vs −2.6 ± 1.1 kg (<em>p</em> = 0.01)), fat mass (−7.7 ± 0.3 kg vs −2.6 ± 0.2 kg (<em>p</em> = 0.01)), waist circumference (−7.2 ± 0.3 cm vs −2.9 ± 0.1 cm (<em>p</em> = 0.01)), glucose levels (−12.1 ± 1.4 mg/dl vs −3.1 ± 1.8 mg/dl, <em>p</em> = 0.01), insulin (−10.8 ± 1.2 UI/L vs −3.9 ± 1.1 UI/L, <em>p</em> = 0.01), HOMA-IR (−2.1 ± 1.0 units vs −0.58 ± 0.2 units, <em>p</em> = 0.01), CRP (−1.2 ± 0.1 mg/dl vs −0.7 ± 0.2 mg/dl, <em>p</em> = 0.01), triglycerides (−22.1 ± 4.1 mg/dl vs −5.1 ± 3.2 mg/dl, <em>p</em> = 0.01), total-cholesterol (−22.2 ± 1.3 mg/dl vs −8.8 ± 1.9 mg/dl, <em>p</em> = 0.01), LDL-cholesterol (−15.2 ± 1.1 mg/dl vs −4.7 ± 1.2 mg/dl, p = 0.01), and HDL-cholesterol (6.2 ± 0.4 mg/dl vs −2.9 ± 1.2 mg/dl, p = 0.01) modifications were better in non-G allele carriers. After intervention, the odds ratio (OR) of MS in non-carrier of G allele improved OR 0.48 (95%CI: 0.31–0.73; <em>p</em> = 0.02).</div></div><div><h3>Conclusions</h3><div>G allele of rs490683 have a deleterious effect on dietary restrictions, body weight and metabolic response after a pMR diet.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 8","pages":"Article 109062"},"PeriodicalIF":2.9,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143923763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antioxidant and anti-inflammatory effects of SMTP-44D in a streptozotocin-induced diabetic neuropathy mouse model","authors":"Ryosuke Shinouchi ,&nbsp;Keita Shibata ,&nbsp;Taiju Nagatsuka ,&nbsp;Keiji Hasumi ,&nbsp;Koji Nobe","doi":"10.1016/j.jdiacomp.2025.109061","DOIUrl":"10.1016/j.jdiacomp.2025.109061","url":null,"abstract":"<div><h3>Background</h3><div>Diabetic neuropathy (DN) is a debilitating complication of diabetes, driven by oxidative stress, inflammation, and advanced glycation end products (AGE) signaling through its receptor (RAGE). Soluble epoxide hydrolase (sEH) metabolizes anti-inflammatory epoxyeicosatrienoic acids (EETs) into pro-inflammatory dihydroxyeicosatrienoic acids (DHETs), exacerbating DN pathology. SMTP-44D, an sEH inhibitor, has demonstrated antioxidant and anti-inflammatory effects in vitro; however, its in vivo efficacy remains unclear.</div></div><div><h3>Aim</h3><div>To investigate the antioxidant and anti-inflammatory activities of SMTP-44D in relation to sEH inhibition and AGE/RAGE signaling in a streptozotocin (STZ)-induced DN mouse model.</div></div><div><h3>Methodology</h3><div>STZ-induced diabetic mice were treated with SMTP-44D (30 mg/kg) from days 8 to 28 post STZ injection (200 mg/kg). Oxidative stress markers, inflammatory factors, AGE in the sciatic nerve, and RAGE in serum were assessed via ELISA. DHET levels in serum were measured using LC-MS/MS, and apoptosis in the sciatic nerve was assessed via TUNEL staining and fluorescent immunohistochemistry for cleaved caspase-3.</div></div><div><h3>Results</h3><div>Our findings indicated that SMTP-44D inhibited sEH, reducing DHET levels and sustaining anti-inflammatory effects. It attenuated the migration of nuclear factor-kappa B, decreased AGE and RAGE levels, and suppressed oxidative stress and inflammatory markers in the sciatic nerve. Moreover, SMTP-44D inhibited apoptosis, potentially mitigating the axonal damage associated with DN.</div></div><div><h3>Conclusion</h3><div>Our findings suggest that SMTP-44D is a promising therapeutic agent for DN, acting through sEH inhibition and reducing AGE/RAGE levels.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109061"},"PeriodicalIF":2.9,"publicationDate":"2025-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143894578","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dietary factors and cancer outcomes in individuals with type 2 diabetes: A systematic review and meta-analysis of prospective observational studies","authors":"Janett Barbaresko ,&nbsp;Alexander Lang ,&nbsp;Tim Benedict Schiemann ,&nbsp;Edyta Schaefer ,&nbsp;Christina Baechle ,&nbsp;Lukas Schwingshackl ,&nbsp;Manuela Neuenschwander ,&nbsp;Sabrina Schlesinger","doi":"10.1016/j.jdiacomp.2025.109060","DOIUrl":"10.1016/j.jdiacomp.2025.109060","url":null,"abstract":"<div><h3>Introduction</h3><div>Cancer is a major health concern in persons with type 2 diabetes (T2D). Diet plays an important role in progression of diabetes and cancer. We aimed to systematically summarize the evidence on diet and cancer in individuals with T2D.</div></div><div><h3>Methods</h3><div>PubMed and Web of Science were searched until August 2023 and followed up via PubMed alert until December 2024. Prospective studies investigating any dietary factor in association with cancer in individuals with T2D were eligible.</div></div><div><h3>Results</h3><div>We identified 68 studies and conducted 20 meta-analyses. A general low-carbohydrate diet was not associated with cancer outcomes, whereas an inverse association was found for vegetable-based low-carbohydrate diet (HR per 5 points [95 % CI]: 0.90 [0.84, 0.97]; <em>n</em> = 2). We found indications of lower cancer incidence for higher adherence to Dietary Approaches to Stop Hypertension diet, (Alternate) Healthy Eating Index, higher intakes of n-3 fatty acids (0.73 [0.55, 0.98]; <em>n</em> = 2) and higher serum vitamin D (0.95 [0.93, 0.97]; <em>n</em> = 2), as well as a positive association for serum manganese concentrations (1.44 [1.11, 1.87]; n = 2), rated with low to very low certainty of evidence.</div></div><div><h3>Conclusion</h3><div>So far, the certainty of evidence is very limited due to the small numbers of primary studies. There is an indication of a possible association between diet and cancer risk among persons with T2D, but further well-designed prospective cohort studies are warranted.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 7","pages":"Article 109060"},"PeriodicalIF":2.9,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143886756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}